Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial.

Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial.

Item
http://www.wikidata.org/entity/Q35939674
FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy.Beyond Cisplatin - IVinflunine in the treatment of advanced urothelial cancer: clinical evidence and experience.Urinary Bladder Cancer: Biomarkers and Target Therapy, New Era for More AttentionEmerging drugs for urothelial (bladder) cancer.Systemic therapy in muscle-invasive and metastatic bladder cancer: current trends and future promises.Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer.High expression of insulin receptor on tumour-associated blood vessels in invasive bladder cancer predicts poor overall and progression-free survival.A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer TherapyRandomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer.A critical review on ramucirumab in the treatment of advanced urothelial cancer.Accelerating Early Access to Immunotherapies for Advanced Urothelial Carcinoma.Emerging first line treatment options for bladder cancer: a review of phase II and III therapies in the pipeline.The New Age of -omics in Urothelial Cancer - Re-wording Its Diagnosis and Treatment.Urothelial cancer in 2017: Changes in expectations for metastatic urothelial carcinoma.Immuno-oncology in urothelial carcinoma: who or what will ultimately sit on the iron throne?Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials
P2860

Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial.

Item
http://www.wikidata.org/entity/Q35939674
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Docetaxel As Monotherapy or Co ...... zed Controlled Phase II Trial.
@ast
Docetaxel As Monotherapy or Co ...... zed Controlled Phase II Trial.
@en
type
label
Docetaxel As Monotherapy or Co ...... zed Controlled Phase II Trial.
@ast
Docetaxel As Monotherapy or Co ...... zed Controlled Phase II Trial.
@en
prefLabel
Docetaxel As Monotherapy or Co ...... zed Controlled Phase II Trial.
@ast
Docetaxel As Monotherapy or Co ...... zed Controlled Phase II Trial.
@en
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
Docetaxel As Monotherapy or Co ...... zed Controlled Phase II Trial.
@en
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P698
P921